Tag: NASDAQ:BCRX

Gilead Sciences GILD NASDAQ:GILD
Finance

Biotech GAiners: BioCryst Pharmaceuticals (NASDAQ:BCRX), Dyax Corp. (NASDAQ:DYAX), Novavax, Inc. (NASDAQ:NVAX), Merrimack Pharmaceuticals Inc (NASDAQ:MACK)

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) shares closed up nearly 11% on Tuesday after the company reported positive data from its OPuS-1 mid-stage study involving BCX4161 as a treatment for hereditary angioedema, or HAE. This is a rare immune disorder that can cause swelling of the face, breathing airways, and also causes abdominal cramping. According to the preliminary results from the company’s proof-of-concept study, BCX4161 met both … Continue reading Biotech GAiners: BioCryst Pharmaceuticals (NASDAQ:BCRX), Dyax Corp. (NASDAQ:DYAX), Novavax, Inc. (NASDAQ:NVAX), Merrimack Pharmaceuticals Inc (NASDAQ:MACK)

Kevin Long
Finance

Bullish Stocks At NASDAQ: Idera Pharmaceuticals Inc (NASDAQ:IDRA), Scientific Games Corp (NASDAQ:SGMS), Origin Agritech (NASDAQ:SEED), BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX)

Idera Pharmaceuticals Inc (NASDAQ:IDRA) issued its quarterly earnings data on Tuesday. The company reported ($0.12) EPS for the quarter, missing the Thomson Reuters consensus estimate of ($0.08) by $0.04, American Banking News reports. Idera Pharmaceuticals Inc (NASDAQ:IDRA) stock performance was 11.02% in last session and finished the day at $2.82. Traded volume was 4,339,672 shares in the last session and the average volume of the … Continue reading Bullish Stocks At NASDAQ: Idera Pharmaceuticals Inc (NASDAQ:IDRA), Scientific Games Corp (NASDAQ:SGMS), Origin Agritech (NASDAQ:SEED), BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX)

Mark Doerr
FB Nasdaq FB Facebook
Finance

Biotech Volatile Stocks: PTC Therapeutics (NASDAQ:PTCT), Agios Pharmaceuticals Inc (NASDAQ:AGIO), BioCryst Pharmaceuticals (NASDAQ:BCRX), TG Therapeutics (NASDAQ:TGTX)

PTC Therapeutics, Inc. (NASDAQ:PTCT) announced a corporate update and reported its financial results for the fourth quarter and full-year ended December 31, 2013. In April 2013, PTC Therapeutics, Inc. (NASDAQ:PTCT) initiated the confirmatory Phase 3 ACT DMD (Ataluren Confirmatory Trial in DMD) clinical trial evaluating ataluren as a potential treatment for patients with nonsense mutation Duchenne muscular dystrophy (nmDMD). PTC Therapeutics, Inc. (NASDAQ:PTCT) stock performance … Continue reading Biotech Volatile Stocks: PTC Therapeutics (NASDAQ:PTCT), Agios Pharmaceuticals Inc (NASDAQ:AGIO), BioCryst Pharmaceuticals (NASDAQ:BCRX), TG Therapeutics (NASDAQ:TGTX)

Colin Pettis
Finance

Healthcare Bearish Stocks: AcelRx Pharmaceuticals (NASDAQ:ACRX), BioCryst Pharmaceuticals (NASDAQ:BCRX), Baxano Surgical (NASDAQ:BAXS), Flamel Technologies (NASDAQ:FLML)

AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, today announced that Richard King, President and CEO will present a Company update. AcelRx Pharmaceuticals Inc (NASDAQ:ACRX) stock performance was -8.38% in last session and finished the day at $11.92. Traded volume was 1.46million shares in the last session and … Continue reading Healthcare Bearish Stocks: AcelRx Pharmaceuticals (NASDAQ:ACRX), BioCryst Pharmaceuticals (NASDAQ:BCRX), Baxano Surgical (NASDAQ:BAXS), Flamel Technologies (NASDAQ:FLML)

Mark DeFrance
BioTech

Biotech Gainers In News: Inovio Pharmaceuticals (NYSEMKT:INO), Dendreon Corporation (NASDAQ:DNDN), BioCryst Pharmaceuticals (NASDAQ:BCRX), Dyax (NASDAQ:DYAX)

Inovio Pharmaceuticals Inc (NYSEMKT:INO) on Feb. 27 announced the pricing of an underwritten public offering of 18,966,000 shares of common stock for a public offering price of $2.90 per share. The gross proceeds to Inovio from this offering are expected to be approximately $55 million, before deducting the underwriting discounts and commissions and other estimated offering expenses payable by the Company. Inovio Pharmaceuticals Inc (NYSEMKT:INO) … Continue reading Biotech Gainers In News: Inovio Pharmaceuticals (NYSEMKT:INO), Dendreon Corporation (NASDAQ:DNDN), BioCryst Pharmaceuticals (NASDAQ:BCRX), Dyax (NASDAQ:DYAX)

Colin Pettis
Finance

Investors Should Watch: Merrimack Pharmaceuticals, Inc. (NASDAQ:MACK), American Airlines Group Inc. (NASDAQ:AAL), General Communication Inc. (NASDAQ:GNCMA), BioCryst Pharmaceuticals (NASDAQ:BCRX), OceanFirst Financial (NASDAQ:OCFC)

On Jan 22, Merrimack Pharmaceuticals, Inc. (NASDAQ:MACK) announced that Birgit M. Schoeberl, Ph.D. has been named the new head of its Discovery division. Ulrik B. Nielsen, Ph.D. will be stepping down as the head of the Discovery division and has been elected to serve on Merrimack’s Board of Directors. Anthony J. Sinskey, Sc.D. will also be resigning from the Board of Directors and will continue … Continue reading Investors Should Watch: Merrimack Pharmaceuticals, Inc. (NASDAQ:MACK), American Airlines Group Inc. (NASDAQ:AAL), General Communication Inc. (NASDAQ:GNCMA), BioCryst Pharmaceuticals (NASDAQ:BCRX), OceanFirst Financial (NASDAQ:OCFC)

Chris Lewis